Contribution of glutathione and glutathione‐dependent enzymes in the reversal of adriamycin resistance in colon carcinoma cell lines
Authors:
- 11 November 1991
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 49 (5) , 688-695
Abstract
Four human colon cancer cell lines (SW620, LS 180, DLD‐I, and HCT‐15) and sub‐lines isolated in vitro by selection with Adriamycin were studied for reversal of intrinsic and acquired Adriamycin resistance, using buthionine sulfoximine (BSO) to deplete cellular glutathione alone and in combination with the P‐glycoprotein antagonist verapamil. GSH levels varied among the parental cell lines but did not increase with resistance. In the parental SW620, DLD‐1 and HCT‐15 and their drugresistant derivatives, there was no relation between the effect of the glutathione‐depleting agent BSO, the mRNA expression of both selenium‐dependent glutathione peroxidase (GPx) and glutathione S‐transferase pi (GSTπ), bulk glutathione S‐trans‐ferase (GST) activity, and the degree of resistance. However, in LS 180 and its derivative sub‐lines, which do not principally rely on P‐glycoprotein (Pgp) for Adriamycin resistance, treatment with BSO demonstrated a relatively diminished GSH depletion and enhanced recovery. In comparison with the other acquired cell lines, BSO specifically reversed acquired resistance in the LS 180 Adriamycin‐resistant subline (LS 180 Ad 150) after short‐term drug exposure. Furthermore, the LS 180 Ad 150 cells demonstrated an increase in both GPx and GSTπ mRNA expression. These observations suggest that glutathione‐mediated detoxification of Adriamycin may play a role in the resistance of this sub‐line. Verapamil enhanced Adriamycin cytotoxicity 1.2‐ to 12‐fold in the intrinsically resistant cells and as much as 15‐fold in cell lines with acquired resistance. Combination of BSO with verapamil resulted in additive, but not synergistic, reversal of resistance. The results underscore the complex nature of Adriamycin resistance, and suggest a role for drug‐resistance‐modulating agents in the treatment of colon carcinoma.Keywords
This publication has 20 references indexed in Scilit:
- P‐glycoprotein expression and schedule dependence of adriamycin cytotoxicity in human colon carcinoma cell linesInternational Journal of Cancer, 1991
- An evaluation of the role of glutathione and its associated enzymes in the expression of differential sensitivities to antitumour agents shown by a range of human tumour cell linesBiochemical Pharmacology, 1990
- Expression of recombinant glutathione S-transferase pi, Ya, or Yb1 confers resistance to alkylating agents.Proceedings of the National Academy of Sciences, 1990
- Role of glutathione and its associated enzymes in multidrug-resistant human myeloma cellsBiochemical Pharmacology, 1989
- Selenocysteine's mechanism of incorporation and evolution revealed in cDNAs of three glutathione peroxidasesProtein Engineering, Design and Selection, 1988
- Role of the Glutathione Redox Cycle in Acquired and de Novo Multidrug ResistanceScience, 1988
- Augmentation of adriamycin, melphalan, and cisplatin cytotoxicity in drug-resistant and -sensitive human ovarian carcinoma cell lines by buthionine sulfoximine mediated glutathione depletionBiochemical Pharmacology, 1985
- Protective role of the glutathione redox cycle against adriamycin-mediated toxicity in isolated hepatocytesBiochemical Pharmacology, 1981
- [51] Assays for differentiation of glutathione S-Transferases1981
- Enzymic method for quantitative determination of nanogram amounts of total and oxidized glutathione: Applications to mammalian blood and other tissuesAnalytical Biochemistry, 1969